Privately held CRO PPD scored two federal contracts tasking it with helping to improve health outcomes for active-duty soldiers and aiding with the government's stockpile of flu vaccines.
WuXi PharmaTech, working to expand the adoption of its new clinical genomics service, partnered up with a large Qatari hospital to sequence the genomes of patients and help guide treatment.
Genae, a med tech-focused CRO, opened a Japanese outpost to broaden its reach, setting up shop in Tokyo with eyes on the growing Asian market for medical devices.
Preclinical CRO Charles River Laboratories brought in three new discovery contracts with outfits funded by the Wellcome Trust, lending its expertise in early-stage drug development.
German drug developer Evotec signed a 5-year, $4.9 million agreement with the National Cancer Institute to help the group build and manage its library of potential oncology drugs.
CRO Frontage is expanding its bioanalytical labs to meet what it says is a spike in client demand, doubling its capacity.
CRO Accelovance has appointed an oncologist with deep roots in drug development to help steer its efforts in cancer R&D, replacing the company's last big get in the field.
PRA Health Sciences has joined forces with a trial site group to focus on vaccine development, hoping to speed up patient recruitment and get more clinical studies rolling.
CRO Chiltern, in the process of integrating its latest acquisition, is focusing in on endocrinology and metabolism, broadening its expertise with an eye on diabetes R&D.
Contract drug developer Patheon is revamping its brand identity on the way to Wall Street, tinkering with its image ahead of a planned $100 million IPO.
Venn Life Sciences is expanding its reach across Europe, buying a small Dutch contractor to bolster its offerings in regulatory affairs.
Chinese contract drug developer ShangPharma is planning to invest $60 million to build a biologics research and manufacturing outpost near its home base in Shanghai.
German preclinical CRO NMI TT Pharmaservices is building a new branch at Bayer's new hub for biotech startups, hoping to expand the use of its discovery platform.
Covance, now a division of LabCorp, is planning to build a second manufacturing-enabled pharmacy adjacent to one of its clinical research sites, allowing the CRO to churn out doses of investigational drugs for ongoing studies.
The acquisitive BioClinica has picked up another service provider, buying a company specializing in safety monitoring and regulatory affairs to build out its offerings in drug development.
U.K. CRO Chiltern has wrapped up its acquisition of former U.S. competitor Theorem Clinical Research, expanding its payroll and global reach in the process.
PRA Health Sciences is building up its presence in Pennsylvania, adding 150 jobs with plans to dial up recruitment over the next two years.
CRO Accelovance is teaming up with a cancer-focused nonprofit to broaden its services in oncology trials, widening its net of expert investigators.
AMRI is brightening its expectations for 2015 after closing its latest buyout, counting on its manufacturing division to keep revenue rolling.
WuXi PharmaTech, making use of its recent $65 million investment in genomics, is teaming up with a Shanghai hospital to expand the scope of precision medicine in its home country.